Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Issue 5 (November 2016)

• Record Type: Journal Article
• Authors: Tadolini, Marina; Lingtsang, Rangjung Dolma; Tiberi, Simon; Enwerem, Martin; D'Ambrosio, Lia; Sadutshang, Tsetan Dorji; Centis, Rosella; Migliori, Giovanni Battista
• Is Part Of: European respiratory journal. Volume 48:Issue 5(2016)
• Page Start: 1527
• Page End: 1529
• Publication Date: 2016-11
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01552-2016
• Languages: English
• ISSNs: 0903-1936

Abstract

We read with great interest the comments by R.S. Wallis on our article describing the first case of extensively drug-resistant tuberculosis (XDR-TB) treated with both delamanid and bedaquiline [1], as recommended by the European Respiratory Society hosted TB Consilium experts [2, 3]. First case, concerns and challenges of treatment of severe XDR-TB with both delamanid and bedaquiline http://ow.ly/8e4l303i0LH